New Tool: ProSource
Check out our packaging and processing solutions finder, ProSource.

Merck’s Ebola Vaccine Won’t See Approval in 2017

With the Ebola epidemic that’s killed 11,000 people looming, Merck & Co. will miss filing its vaccine for FDA approval this year.

Merck / Image: FiercePharma
Merck / Image: FiercePharma

The FDA has made an effort to expedite Ebola vaccines through the approval process, but according to a recent FiercePharma article, Merck will miss its goal of filing this year. Merck spokeswoman Pamela Eisele noted that they are “committed to developing and seeking approval for [their] Ebola vaccine as quickly as possible,” and they expect to file for approval with a “major regulatory agency in 2018.”

Merck was granted a $5 million advance purchase commitment from the Gavi, the Vaccine Alliance, but the deal was contingent on the company filing the vaccine for approval by the end of 2017. A spokesperson from Gavi said that the agreement “should not be substantively affected” by the delayed filing.

Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Read More
Test Your Supply Chain Smarts
Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Read More
Discover Our Content Hub